Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in Relapsed/Refractory DLBCL
NCT01741792Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2012
- Primary completion
- Jul 2014
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in diffuse large B-cell lymphoma (DLBCL), sponsored by Amgen. Started Jul 2012; status: completed.
02
Drugs
blinatumomab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01741792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01741792.